I've heard people mention that researchers time would be better spent designing treatments for progressive MS and it really does seem that is true. Sadly, because 85% of the patients have RRMS and that is where the vast majority of treatment profits stand to be made, designing RRMS treatments is all that anyone has ever been able to bring themselves to focus on.
If you know of or happen to run across any documentation I'd REALLY be interested to know the real percentages in the different phases of living MS'rs.
cheerleader wrote:Hey Bob and GWA-
I'd love to see those percentages, too!
Thanks for clearing up that 85% at time of diagnosis, GWA. I was also confused by that number.
Wonder how many MSers leave this planet with RR?
Or what's the percentage of RR MSers in the 40 year + age group? Also curious if those who utilized CRABs in the beginning of their disease process have shown any long-term gains.
Agree with the need to end competitive , back-patting studies, GWA.
A total of 10.5% of patients had primary progressive, 47.6% relapsing-remitting, and 33.3% secondary progressive disease.
Nessabear wrote:I've always thought that one of the main reasons the drug companies focus on treatments for RRMS is that it is the only phase of the disease in which they have any chance at all of making their outrageously expensive treatments look successful. By focusing solely on RRMS, they are dealing with people in early stage of the disease and likely producing statistics that look good in part due to naturally occurring remissions and lower levels of disability. Perhaps it's just my rampant cynicism gone wild...
Users browsing this forum: No registered users